Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2020-12-24T16:30:13Z | - |
dc.date.available | 2020-12-24T16:30:13Z | - |
dc.date.issued | 2020 | * |
dc.identifier.issn | 0007-1048 | * |
dc.identifier.issn | 1365-2141 | * |
dc.identifier.other | OAK-28452 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/255817 | - |
dc.description.abstract | In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice-daily radotinib 300 mg (n = 79) or 400 mg (n = 81) than with once-daily imatinib 400 mg (n = 81) after 12 months. With >= 48 months' follow-up, MMR was higher with radotinib 300 mg (86%) or 400 mg (83%) than with imatinib (75%). Among patients with BCR-ABL1 <= 10% at three months, MMR and molecular response 4 center dot 5 (MR4 center dot 5) were achieved within 48 months by more radotinib-treated patients (300 mg: 84% and 52%, respectively; 400 mg: 74% and 44%, respectively) than imatinib-treated patients (71% and 44%, respectively). Estimated overall and progression-free survival rates at 48 months were not significantly different between imatinib (94% and 94%, respectively) and radotinib 300 mg (99% and 97%, respectively) or 400 mg (95% and 93%, respectively). The treatment failure rate was significantly higher with imatinib (19%) than with radotinib 300 mg (6%; P = 0 center dot 0197) or 400 mg (5%; P = 0 center dot 0072). Safety profiles were consistent with previous reports; most adverse events occurred within 12 months. Radotinib continues to demonstrate robust, deep molecular responses, suggesting that treatment-free remission may be attainable. | * |
dc.language | English | * |
dc.publisher | WILEY | * |
dc.subject | chronic myeloid leukaemia | * |
dc.subject | imatinib | * |
dc.subject | newly diagnosed | * |
dc.subject | long-term data | * |
dc.subject | radotinib | * |
dc.title | Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 189 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 303 | * |
dc.relation.lastpage | 312 | * |
dc.relation.journaltitle | BRITISH JOURNAL OF HAEMATOLOGY | * |
dc.identifier.doi | 10.1111/bjh.16381 | * |
dc.identifier.wosid | WOS:000510537100001 | * |
dc.author.google | Do, Young Rok | * |
dc.author.google | Kwak, Jae-Yong | * |
dc.author.google | Kim, Jeong A. | * |
dc.author.google | Kim, Hyeoung Joon | * |
dc.author.google | Chung, Joo Seop | * |
dc.author.google | Shin, Ho-Jin | * |
dc.author.google | Kim, Sung-Hyun | * |
dc.author.google | Bunworasate, Udomsak | * |
dc.author.google | Choi, Chul Won | * |
dc.author.google | Zang, Dae Young | * |
dc.author.google | Oh, Suk Joong | * |
dc.author.google | Jootar, Saengsuree | * |
dc.author.google | Reksodiputro, Ary Harryanto | * |
dc.author.google | Lee, Won Sik | * |
dc.author.google | Mun, Yeung-Chul | * |
dc.author.google | Kong, Jee Hyun | * |
dc.author.google | Caguioa, Priscilla B. | * |
dc.author.google | Kim, Hawk | * |
dc.author.google | Park, Jinny | * |
dc.author.google | Kim, Dong-Wook | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |